Hereditary transthyretin amyloidosis (ATTRv) is a rare, debilitating and fatal disease, mostly characterized by progressive axonal peripheral neuropathy. Diagnosis is still challenging and diagnostic delay in non-endemic area is about 3-4 years. The aim of this study was to arrange a clinical and electrophysiological score to select patients with axonal neuropathy that deserve screening for TTR mutation.
A compound score to screen patients with hereditary transthyretin amyloidosis / Tozza, S., Severi, D., Spina, E., Di Paolantonio, A., Iovino, A., Guglielmino, V., Aruta, F., Nolano, M., Sabatelli, M., Santoro, L., Luigetti, M., Manganelli, F.. - In: JOURNAL OF NEUROLOGY. - ISSN 0340-5354. - 269:8(2022), pp. 4281-4287. [10.1007/s00415-022-11056-4]
A compound score to screen patients with hereditary transthyretin amyloidosis
Tozza, Stefano;Severi, Daniele;Spina, Emanuele;Iovino, Aniello;Aruta, Francesco;Nolano, Maria;Santoro, Lucio;Manganelli, Fiore
2022
Abstract
Hereditary transthyretin amyloidosis (ATTRv) is a rare, debilitating and fatal disease, mostly characterized by progressive axonal peripheral neuropathy. Diagnosis is still challenging and diagnostic delay in non-endemic area is about 3-4 years. The aim of this study was to arrange a clinical and electrophysiological score to select patients with axonal neuropathy that deserve screening for TTR mutation.| File | Dimensione | Formato | |
|---|---|---|---|
|
415_2022_Article_11056.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
830.83 kB
Formato
Adobe PDF
|
830.83 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
